Compare Dr. Reddys with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WOCKHARDT - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WOCKHARDT DR. REDDYS LAB/
WOCKHARDT
 
P/E (TTM) x 22.3 -22.2 - View Chart
P/BV x 3.3 1.2 285.8% View Chart
Dividend Yield % 0.7 0.0 21,431.1%  

Financials

 DR. REDDYS LAB   WOCKHARDT
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
WOCKHARDT
Mar-18
DR. REDDYS LAB/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs2,8751,012 284.1%   
Low Rs1,888532 355.2%   
Sales per share (Unadj.) Rs930.2355.9 261.4%  
Earnings per share (Unadj.) Rs117.4-60.3 -194.8%  
Cash flow per share (Unadj.) Rs185.8-46.8 -397.2%  
Dividends per share (Unadj.) Rs20.000.01 200,000.0%  
Dividend yield (eoy) %0.80 64,812.1%  
Book value per share (Unadj.) Rs844.4257.8 327.5%  
Shares outstanding (eoy) m166.07110.63 150.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.2 118.1%   
Avg P/E ratio x20.3-12.8 -158.4%  
P/CF ratio (eoy) x12.8-16.5 -77.7%  
Price / Book Value ratio x2.83.0 94.2%  
Dividend payout %17.00 -102,669.6%   
Avg Mkt Cap Rs m395,49685,379 463.2%   
No. of employees `00022.06.3 351.2%   
Total wages/salary Rs m33,5629,371 358.2%   
Avg. sales/employee Rs Th7,032.86,295.0 111.7%   
Avg. wages/employee Rs Th1,527.91,498.3 102.0%   
Avg. net profit/employee Rs Th887.7-1,066.3 -83.3%   
INCOME DATA
Net Sales Rs m154,48239,369 392.4%  
Other income Rs m3,3751,202 280.7%   
Total revenues Rs m157,85740,571 389.1%   
Gross profit Rs m31,78218 173,672.1%  
Depreciation Rs m11,3481,495 758.9%   
Interest Rs m8892,555 34.8%   
Profit before tax Rs m22,920-2,830 -810.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m3,858257 1,501.2%   
Profit after tax Rs m19,500-6,669 -292.4%  
Gross profit margin %20.60 44,259.5%  
Effective tax rate %16.8-9.1 -185.3%   
Net profit margin %12.6-16.9 -74.5%  
BALANCE SHEET DATA
Current assets Rs m111,10133,796 328.7%   
Current liabilities Rs m58,97326,917 219.1%   
Net working cap to sales %33.717.5 193.1%  
Current ratio x1.91.3 150.0%  
Inventory Days Days7979 100.0%  
Debtors Days Days9489 105.6%  
Net fixed assets Rs m101,24539,664 255.3%   
Share capital Rs m830553 150.0%   
"Free" reserves Rs m139,40627,968 498.4%   
Net worth Rs m140,23628,522 491.7%   
Long term debt Rs m22,00021,731 101.2%   
Total assets Rs m224,65681,620 275.2%  
Interest coverage x26.8-0.1 -24,908.9%   
Debt to equity ratio x0.20.8 20.6%  
Sales to assets ratio x0.70.5 142.6%   
Return on assets %9.1-5.0 -180.1%  
Return on equity %13.9-23.4 -59.5%  
Return on capital %14.9-7.7 -194.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,6739,807 904.2%   
Fx outflow Rs m19,1041,789 1,068.1%   
Net fx Rs m69,5698,019 867.6%   
CASH FLOW
From Operations Rs m28,704684 4,194.0%  
From Investments Rs m-7,7276,302 -122.6%  
From Financial Activity Rs m-21,326-7,695 277.2%  
Net Cashflow Rs m-314-664 47.3%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 2.3 234.8%  
FIIs % 35.3 7.7 458.4%  
ADR/GDR % 18.5 0.1 18,500.0%  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 67,757 112.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS